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ApoptosisCM) from mouse NIH3T3 ﬁbroblast cells overexpressing phosphatidylinositol
transfer protein α (PI-TPα; SPIα cells) demonstrates an increased anti-apoptotic activity compared with CM
fromwild type NIH3T3 (wtNIH3T3) cells. As previously shown, the anti-apoptotic activity acts by activating a
G protein-coupled receptor, most probably a cannabinoid 1 (CB1)-like receptor as the activity was blocked by
both pertussis toxin and rimonabant [M. Schenning, C.M. van Tiel, D. Van Manen, J.C. Stam, B.M. Gadella, K.W.
Wirtz and G.T. Snoek, Phosphatidylinositol transfer protein alpha regulates growth and apoptosis of NIH3T3
cells: involvement of a cannabinoid 1-like receptor, J. Lipid Res. 45 (2004) 1555–1564]. The CB1 receptor
appears to be expressed in mouse ﬁbroblast cells, at levels in the order SPIαNwtNIH3T3NSPIβ cells (i.e. wild
type cells overexpressing PI-TPβ). Upon incubation of SPIβ cells with the PI-TPα-dependent anti-apoptotic
factors, both the ERK/MAP kinase and the Akt/PKB pathway are activated in a CB1 receptor dependent
manner as shown by Western blotting. In addition, activation of ERK2 was also shown by EYFP-ERK2
translocation to the nucleus, as visualized by confocal laser scanning microscopy. The subsequent activation
of the anti-apoptotic transcription factor NF-κB is in line with the increased resistance towards UV-induced
apoptosis. On the other hand, receptor activation by CM from SPIα cells was not linked to phospholipase C
activation as the YFP-labelled C2-domain of protein kinase C was not translocated to the plasma membrane
of SPIβ cells as visualized by confocal laser scanning microscopy.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Phosphatidylinositol transfer protein α (PI-TPα) is a small, ubiqui-
tously expressed protein belonging to a family of highly conserved
proteins that in vitro transfers phosphatidylinositol (PI) and phospha-
tidylcholine (PC) between membranes [2,3]. In mammalian tissues,
two soluble, highly homologous isoforms are identiﬁed: PI-TPα, local-
ized in the nucleus and cytosol and PI-TPβ, associated with the Golgi
membrane [4–7]. Cellular functions of these proteins comprise the
stimulation of secretory vesicle formation from isolated Golgi mem-
branes, PImetabolismand inositol lipid signalling [8–11]. Furthermore, aotein; PI, phosphatidylinositol;
K, mitogen-activated protein
inhibitor of apoptosis protein;
protein kinase C; YFP, yellow
EM, Dulbecco's modiﬁed Eagle
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uffered saline; PMSF, phenyl-
protein-coupled receptor
logy, College of Life Sciences,
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enning).
l rights reserved.decreased expression of PI-TPα and PI-TPβ was demonstrated in aged
brain and in Parkinson's disease, linking PI-TPs to neurodegenerative
diseases [12–14]. This was supported by the ﬁnding that PI-TPα−/−mice
died within 14 days after birth as a result of spinocerebellar disease
characteristics, hypoglycemia, and intestinal steatosis [13]. Lethality of
PI-TPβ gene ablation and difference in localization emphasizes that the
PI-TP isoforms have separate physiological functions. A reduced
expression of PI-TPα in rat WRK mammary tumour cells was reﬂected
in a decreased rate of proliferation [9]. On the other hand, wtNIH3T3
mouse ﬁbroblast cells expressing an increased level of PI-TPα (SPIα
cells) have an enhanced rate of proliferation and are highly resistant
towards UV- or tumour necrosis factor α-induced apoptosis [1,10]. We
previously showed that the SPIα cells secrete mitogenic and anti-
apoptotic arachidonic metabolites, the production of which is partially
dependent on cyclooxygenase 2 [1]. The anti-apoptotic activity acts via
activation of a G protein-coupled receptor, more speciﬁcally a canna-
binoid 1-like receptor, as it was blocked by pertussis toxin and speciﬁc
CB1 receptor antagonist rimonabant [1].
Several signalling pathways linking GPCRs (i.e. CB1 receptor) acti-
vation to cell survival have been described. It was shown that upon
CB1 receptor activation the p42/p44 mitogen-activated protein kinase
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eukaryotic organisms [15–20]. The MAP kinase pathway is stimulated
upon binding of extracellular signals to both tyrosine kinase receptors,
G protein-coupled receptors and cytokine receptors. Receptor activa-
tion leads to the subsequent phosphorylation of Ras, Raf, MEK
(MAPKK), and extracellular signalling related kinase (ERK1/2)
(reviewed in [21]). Upon activation of MEK, the MEK/ERK complex
dissociates by which ERK1/2 is phosphorylated and translocated into
the nucleus where it phosphorylates transcription factors [22–24]. It
has been reported that ERK affects apoptosis by promoting expression
of IAPs (inhibitor of apoptosis protein) [25–27].
A second signalling pathway linking CB1 receptor activation to cell
survival is the Akt/PKB pathway [15]. Similar to p42/p44 MAPK, Akt/
PKB has emerged as a key regulatory factor in several cellular func-
tions such as cell growth, transcriptional regulation and cell survival
[28]. Akt/PKB is a downstream effector of PI 3-kinase, which is
activated by tyrosine kinase and G protein-coupled receptors [29].
Upon receptor activation, PI 3-kinase gives rise to an increased PI
(3,4,5)P3 formation. PIP3 recruits Akt/PKB to the plasma membrane
where it is activated by phosphorylation. In addition, it has been
reported that Akt/PKB can be activated via protein kinase A [30,31].
Upon activation, Akt/PKB has a direct effect on cell survival by in-
hibiting the pro-apoptotic Bcl-2 related protein, BAD and by inhibiting
caspases 9. Furthermore, Akt/PKB affects apoptosis on a transcrip-
tional level both by activation of NF-κB and CREB, which regulate the
transcription of pro-survival genes like Bcl-xL, caspases inhibitors and
by inhibition of YAK and Forkhead, which regulate the transcription of
pro-apoptotic genes like JNK and Bax [32–36].
Herewe provide evidence that the PI-TPα-dependent anti-apoptotic
factors activate both the p42/p44MAP kinase pathway and the Akt/PKB
pathway via activation of the CB1 receptor. Subsequently, the anti-
apoptotic transcriptional factor NF-κB is activated resulting in nuclear
translocation.
2. Materials and methods
2.1. Materials
Anti-P-MAP kinase, anti-ERK1/2, anti-P-Akt/PKB, anti-IκBα and anti-P-IκBα anti-
bodies were obtained from Cell Signaling technology. DMEM and Lipofectamine 2000
were obtained from Invitrogen. Cannabinoid 1 receptor antibody was a kind gift of
Maurice R. Elphick (School of Biological Sciences, Queen Mary and Westﬁeld College,
University of London). YFP-ERK2 was a kind gift of Andrey Shaw (Department of
Pathology and Immunology, Washington University School of Medicine, St. Louis, USA).
C2-YFP was a kind gift of Tobias Meyer (Department of Molecular Pharmacology,
StanfordUniversityMedical Center, Stanford, USA). The cannabinoid receptor antagonist
SR141716Awas a kind gift of Dr. G. van Zadelhoff (Section Bioorganic Chemistry, Bijvout
Center, Utrecht Univerity).
2.2. Cell culture
All cells were cultured in Dulbecco's modiﬁed Eagles medium (DMEM) containing
10% newborn calf serum (NCS) and buffered with 44 mM NaHCO3. Cells were
maintained at 7.5% CO2 at 37 °C in a humidiﬁed atmosphere. Wild type cells used were
designated ATCC CRL 1658 NIH3T3 cells. wtNIH3T3 mouse ﬁbroblast cells over-
expressing PI-TPα (SPIα cells) were obtained as described in Snoek et al. [10]. The
mouse ﬁbroblast cells overexpressing PI-TPβ (SPIβ cells) were obtained as described in
van Tiel et al. [37].
2.3. Preparation of conditioned medium
Cells were grown to 90% conﬂuency in 150 cm2 dishes. After washing the cells twice
with PBS, the medium was replaced with 13 ml of DMEM/bicarbonate containing 0.1%
bovine serum albumin (DBB medium). After 24 h the medium was collected and cen-
trifuged (10 min at 1000 rpm) to remove ﬂoating cells. The supernatant is the condi-
tioned medium (CM). Under standard conditions 90% conﬂuent cells were incubated
with CMderived froman identical surface of cells (i.e. 9.5 cm2 of cells per well of a 6-well
dish was incubated with the amount of CM derived from 9.5 cm2 of cells).
2.4. Induction of apoptosis by UV irradiation
Cells were seeded in 6-well plates and grown for 48 h until ca 90% conﬂuency.
Growth medium was removed and cells were washed with PBS. Prior to UV irradia-tion cells were incubated with either DBB medium or conditioned medium for 4 h.
The medium was removed and the cells were given a dose of UV light (200 J/m2)
using a Stratalinker (Stratagene). After UV irradiation the cells were incubated with
DBB at 37 °C. At the indicated time points cell death was morphologically deter-
mined as the percentage of cells that are in the process of blebbing. In addition,
apoptosis was characterized by staining with 4′,6-diamidino-2-phenyindole (DAPI)
visualizing condensed DNA or stained with annexin V visualizing phosphatidylserine
externalization.
2.5. Membrane isolation
Cells were grown to 90% conﬂuency in 150 cm2 dishes. After washing the cells twice
with PBS, the cells were scrapped off in 3 ml lysis buffer (0.1% NP40, 20 mM Tris-HCl,
150 mM NaCl, pH 7.6). The cell suspension was sonicated (two 10-s bursts) on ice.
Nuclei and cell debris were removed from the homogenate by centrifugation at
17,500 ×g from 10 min. The resulting supernatant was centrifuged at 100,000 ×g for 3 h
at 4 °C (SW40 rotor, Beckman ultracentrifuge). The membrane pellet was solubilized in
buffer (1% Triton X-100, 20 mM Tris-HCl, pH 7.6) by sonication (three 10-s bursts on ice)
and the protein content was determined using the Bradford assay. Equal amounts of
membrane proteins were subjected to non-reducing SDS-PAGE on a 12% gel and
Western blot analysis was performed using a CB1 receptor speciﬁc antibody. The blot
was stained with ponceau S and scanned to determine whether equal amounts of
protein were analysed. The speciﬁcity of the CB1 receptor staining was established by
pre-absorption of the afﬁnity-puriﬁed antibody with the CB1 C-terminal peptide anti-
gen (20 μM) for 1 h before incubation.
2.6. Sample preparation for Western blot analysis
Cells were grown in 21 cm2 dishes to 80–90% conﬂuency, serum starved for 4 h
and incubated with CM for the indicated times. Cells were washed twice with PBS
(ice-cold) and lysed in 20 mM Tris–HCl pH 7.5 containing 0.1% (v/v) NP40, 10 mM
β-glycerophosphate, 1 mM Na3VO4, 50 mM NaF, 1 mM aprotinin and 1 mM PMSF. Cells
were scraped off and transferred to an Eppendorf tube. Cell lysates were centrifuged at
17,500 ×g for 10 min at 4 °C and the protein content of the supernatant fractions
determined using the Bradford assay [38]. Equal amounts of supernatant proteins
(50 μg) were subjected to SDS-PAGE on a 12% gel and Western blot analysis was
performed using speciﬁc antibodies. To determine whether equal amounts of protein
were analysed, blot were stained with ponceau S and scanned. Bands on the immu-
noblot were quantiﬁed using a Bio-Rad GS700 imaging densitometer equipped with an
integrating program.
2.7. Fluorescence microscopy
Cells were seeded in 6-well plates containing 24 mm Ø coverslips. The next day,
cells were transfected with 1 μg puriﬁed plasmid DNA using Lipofectamine 2000
(Invitrogen, Breda, The Netherlands). One day after transfection the coverslip was
mounted in a home made chamber or an Attoﬂuor cell chamber fromMolecular Probes
(Leiden, The Netherlands). Cells were observed and imaged on a LSM510 (Zeiss,
Germany) confocal laser scanning microscope. A Zeiss 63′ oil-immersion objective
(Plan-Apochromat, NA 1.4) was used. YFP was excited using the 488 nm laser line,
which was reﬂected onto the sample by a 488 nm dichroic mirror. YFP ﬂuorescence was
passed through a 505–550 nm bandpass ﬁlter and detected with a pinhole setting
corresponding to 1 airy unit.
2.8. Data analysis
The average nuclear ﬂuorescence (YFP-ERK2) or membrane/cytosolic ﬂuorescence
(C2-YFP) of a single cell was measured at every time-point by selecting a region of
interest (ROI) in the right area using the Zeiss LSM510 software version 3.2. The initial
value was normalized to 1. Graphs were prepared using Kaleidagraph 3.6 (Synergy
software, Reading, PA).
3. Results
3.1. Anti-apoptotic activity of CM from SPIα and wtNIH3T3 cells
Previously, we have shown that wtNIH3T3 cells overexpressing
PI-TPα (SPIα cells) produce and secrete potent mitogenic and anti-
apoptotic factors [1]. The mechanism by which PI-TPα regulates the
production of these mitogenic and anti-apoptotic factors is discussed
in Schenning et al. [1]. As shown in Fig. 1, SPIβ cells are fully protected
against UV-induced apoptosis upon incubate for 4 h with CM from
SPIα cells. SincewtNIH3T3 cells contain an endogenous level of PI-TPα
and are known to producemitogenic ant anti-apoptotic factors [39,40],
CM fromwtNIH3T3 cells also expresses anti-apoptotic activity, yet to a
lesser extent (Fig. 1). This difference in anti-apoptotic activity reﬂects
the levels of PI-TPα in these cells.
Fig. 1. Survival of SPIβ cells upon induction of apoptosis by ultraviolet (UV) irradiation.
SPIβ cells were grown to 90% conﬂuency and incubated from 4 h at 37 °C with DMEM/
Bic/0.1% bovine serum albumin (DBB), CM from wtNIH3T3 or CM from SPIα cells. After
removing the media, the cells were irradiated with a dose of UV light (200 J/m2), fresh
DBB was added to the cells and incubated for 3 h at 37 °C. The number of apoptotic cells
(blebbing) was determined by visual analysis at the indicated times. Results±SD
represent the mean values of at least three experiments.
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Previously it was shown that the CB1 receptor antagonist
SR141716A inhibits the anti-apoptotic activity of CM from SPIα cells
[1]. Western blot analysis of the membrane fractions of wtNIH3T3,
SPIα and SPIβ cells using afﬁnity-puriﬁed antibodies against the CB1
receptor revealed immunoreactive bands at ~41, ~53 and ~62 kDa. The
antibody used has been raised against the C-terminal 13 amino acids
of the receptor and has previously been shown to be speciﬁc for the
CB1 receptor [41,42]. The immunoreactive ~53 kDa band corresponds
with the predicted molecular weight of the full length CB1 receptor,
whereas the ~62 kDa band is consistent with the glycosylated isoform
of the CB1 receptor detected previously in rat brain [41–43] (Fig. 2).
The immunoreactive ~41 kDa bandmay have resulted from previously
described N-terminal enzymatic degradation or may be an alterna-Fig. 2. Expression of cannabinoid 1 receptor in wtNIH3T3, SPIα and SPIβ cells. Cells
were grown to 90% conﬂuency and membrane enriched fractions were prepared as
described in Materials and methods. Equal amounts of membrane proteins (40 μg) from
wtNIH3T3, SPIβ and SPIβS262A cells were separated on an 8% polyacrylamide, Tris–
glycine gel under non-reducing conditions. The proteins were transferred from the gel
to nitrocellulose and subjected to Western blot analysis using an afﬁnity-puriﬁed
cannabinoid 1 receptor antibody. To check whether equal amounts of protein were
analysed, blots were stained with ponceau S and scanned.tively spliced isoform of the CB1 receptor comparable to the CB1A
isoform in humans [44,45] (Elphick M.R., personal communication).
The speciﬁcity of CB1 staining was established by blocking the
afﬁnity-puriﬁed antibody with the CB1 C-terminal peptide antigen.
This pre-absorption abolished CB1 staining (all three immunoreactive
bands) when using the antibody for Western blot analysis. The full
length CB1 receptor appears to be prominently present in SPIα cells
and to some extent in wtNIH3T3 cells. Moreover, the immunoreactive
band at ~41 kDa and ~62 kDa appear to be present to equal extents in
wtNIH3T3 and SPIα cell and to a lesser extent in SPIβ cells.
3.3. P42/P44 MAP kinase activation
Given that both CM from wtNIH3T3 and SPIα cells exhibited anti-
apoptotic activity and since it has been reported that the CB1 receptor
activates the p42/p44 MAP kinase pathway [46], we investigated the
involvement of this pathway. Incubation of SPIβ cells with CM from
SPIα cells gave rise to a rapid phosphorylation of p42/p44 MAP kinase
over a time period of 30 min (Fig. 3A; left panel). After 1 h the level ofFig. 3. A. Phosphorylation of p42/p44MAP kinase in SPIβ cells upon incubationwith CM
from wtNIH3T3 or SPIα cells. SPIβ cells were grown to 90% conﬂuency, serum starved
for 4 h and incubated for the indicated times with CM from SPIα or wtNIH3T3 cells at
37 °C. Equal amounts of cell lysate protein (25 μg) were subjected to SDS-PAGE followed
by Western blot analysis using a p42/p44 MAP kinase speciﬁc antibody. To check
whether equal amounts of protein were analysed, blots were stained with ponceau S
and scanned. Representative experiment performed in triplicate. B. Confocal images of
SPIβ cells transfected with EYFP-ERK2 before (t=0 s) and after stimulation with CM
from SPIα cells (t=900 s). The relative ﬂuorescence intensity in the nucleus of the cell
indicated with the arrowhead is quantiﬁed and shown in the graph (initial ﬂuorescence
is normalized to 1). The black bar indicates the presence of CM from SPIα cells. Width of
a single image is 146 μm. Representative experiment performed in triplicate.
Fig. 4. Phosphorylation of Akt/PKB in SPIβ cells upon incubation with CM from
wtNIH3T3 or SPIα cells. SPIβ cells were grown to 90% conﬂuency, serum starved for 4 h
and incubated for the indicated times with CM from SPIα or wtNIH3T3 cells at 37 °C.
Equal amounts of cell lysate protein (50 μg) were subjected to SDS-PAGE followed by
Western blot analysis using a P-Akt/PKB speciﬁc antibody. To check whether equal
amounts of protein were analysed, blots were stained with ponceau S and scanned.
Representative experiment performed in triplicate.
Fig. 5. NF-κB activation in SPIβ cells upon incubation with CM from wtNIH3T3 or SPIα
cells. SPIβ cells were grown to 90% conﬂuency, serum starved for 4 h and incubated for
the indicated times with CM from SPIα or wtNIH3T3 cells at 37 °C. Equal amounts of
cytosolic protein (25 μg) were subjected to SDS-PAGE followed byWestern blot analysis
using an IκBα or P-IκBα speciﬁc antibody visualizing clearance from the cytosol. To
check whether equal amounts of protein were analysed, blots were stained with
ponceau S and scanned. Representative experiment performed in triplicate.
Fig. 6. Effect of CB1 receptor antagonist SR141716A on the activation of the p42/p44MAP
kinase, Akt/PKB, and NF-κB pathways upon incubation with CM from SPIα cells. SPIβ
cells were grown to 90% conﬂuency and incubated for the indicated times with CM from
SPIα cells in the presence or absence of SR141716A. Equal amounts of cell lysate protein
were subjected to SDS-PAGE followed by Western blot analysis using an ERK1/2, p42/
p44 MAP kinase, P-Akt/PKB, or P-IκBα speciﬁc antibody visualizing pathway activation.
To check whether equal amounts of protein were analysed, blots were stained with
ponceau S and scanned. Representative experiment performed in triplicate.
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was much less upon incubation with CM from wtNIH3T3 cells (right
panel) most likely reﬂecting the difference in anti-apoptotic activity.
Previously, it was shown that activation of ERK2 (p42 MAP kinase)
is paralleled by translocation of a ﬂuorescent-tagged ERK2 into the
nucleus [47]. To visualize the activation of the p42/p44 MAP kinase
pathway with high spatial–temporal resolution in single living cells,
SPIβ cells were transiently transfected with YFP-tagged ERK2 [48]. In
resting cells, ERK2 is predominantly located in the cytoplasm. Upon
addition of CM from SPIα cells, a clear accumulation of ERK2 in the
nucleus was observed (Fig. 3B). A rapid initiation of the ERK2 trans-
location was shown, attaining a maximum within 10 min (Fig. 3B).
These data agree very well with the rapid activation of the p42/p44
MAP kinase pathway observed by Western blot analysis. Combined,
these data show that the additional anti-apoptotic factors present in
CM from SPIα cells induce a transient and increased activation of the
p42/p44 MAP kinase pathway compared with CM from wtNIH3T3
cells.
3.4. Akt/PKB and NF-κB activation
To further establish the mode of action of the PI-TPα-dependent
anti-apoptotic activity, the involvement of the Akt/PKB signalling
pathway was studied by Western blot analysis using the antibody
against Ser-473. Upon incubation of SPIβ cells with CM from SPIα
cells, Akt/PKB was phosphorylated to a maximum extent at 10 min
(Fig. 4). For comparison, CM fromwtNIH3T3 cells induced very limited
Akt/PKB phosphorylation.
Since the activation of both the p42/p44 MAP kinase pathway and
the Akt/PKB pathway can result in NF-κB activation, we investigated
the effect of CM fromwtNIH3T3 and SPIα cells on the activation of this
anti-apoptotic transcription factor. NF-κB is retained in the cytoplasm
in an inactive form by association with IκBα, the intracellular NF-κB
inhibitor. Upon phosphorylation of IκBα by IKK (IκB kinase com-
plexes), the IκBα/NF-κB complex dissociates and p-IκBα is ubiquiti-
nated and subsequently degraded in proteasomes. Phosphorylation of
IκBα at Ser32 and the clearance of IκBα from the cytosolic fraction
indicate NF-κB activation. In agreement with the activation of the
above pathways, incubation with CM from SPIα cells (10 min) gave
rise to phosphorylation of IκBα (Fig. 5; lower left panel). Concomi-
tantly, IκBα was cleared from the cytosol and reappeared again after
40 min (Fig. 5; upper left panel). For comparison, incubation of SPIβ
cells with CM from wtNIH3T3 cells showed less and a slower
phosphorylation of IκBα and some clearance of IκBα from the cytosol
(Fig. 5; right panels). This indicates that the supplementary anti-
apoptotic factors present in CM from SPIα cells result in an increased
NF-κB activation.
To further establish the role of the CB1 receptor, we investigated
the effect of SR141716A (a speciﬁc CB1 receptor antagonist) on the
activation of the p42/p44 MAP kinase, Akt/PKB, and NF-κB pathways
by CM from SPIα cells. As previously shown, incubation of SPIβ cellswith CM from SPIα cells activated all three pathways within 10 min
(Fig. 6; left panel). Upon incubation of SPIβ cells with CM from SPIα
cells in the presence of SR141716A, the activation of both the p42/p44
MAP kinase pathway and the Akt/PKB pathway was signiﬁcantly
reduced (Fig. 6; right panel). Subsequently, NF-κB inhibitor protein
IκBα was phosphorylated to a lesser extent. This implies that the CB1
receptor mediates the effect of the PI-TPα-dependent anti-apoptotic
factors on the p42/p44 MAP kinase, Akt/PKB, and NF-κB pathways.
3.5. Phospholipase C activation
Since several reports show that PI-TPα is involved in G protein-
coupled receptor-mediated activation of phospholipase C (PLC) [11],
we investigated whether the PI-TPα-dependent survival factor could
play a role in the activation of PLC. It has been demonstrated that the
calcium-sensitive C2 domain of protein kinase C fused to YFP (C2-YFP)
is a sensitive reporter of PLC-mediated release of intracellular calcium
Fig. 7. Confocal images of SPIβ cells transfected with the C2 of protein kinase C tagged
with YFP before (t=0s) and just after stimulation with 100 μM UTP (t=108s). The
ﬂuorescence ratio of membrane/cytosol of the cell indicated with the arrowhead is
quantiﬁed and shown in the graph (initial ﬂuorescence is normalized to 1). The black
bars indicate the presence of CM from SPIα and UTP in the medium. Width of a single
image is 146 μm.
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the C2-YFP is translocated to the plasma membrane. SPIβ cells
transiently transfected with C2-YFP displayed a homogeneous
distribution of yellow ﬂuorescence in the cytoplasm and nucleus
(Fig. 7A). Upon incubation with CM from SPIα cells the distribution
remained unchanged. However, upon addition of uridine triphosphate
(UTP; a potent PLC activator) the C2-YFP accumulated at the plasma
membrane. This indicates an increase in intracellular calcium followed
by PLC activation (Fig. 7A). Quantiﬁcation of the ratio of membrane/
cytosol ﬂuorescence showed no change in the ratio due to CM from
SPIα but a fast and transient increase in the ratio upon addition of UTP
(Fig. 7B). These data indicate that CM from SPIα does not activate PLC.
This is in agreement with previous observations that the activation of
the CB1 receptor is not linked to PLC activation [51].
4. Discussion
We have previously shown that wtNIH3T3 mouse ﬁbroblast cells
overexpressing PI-TPα (SPIα cells) produce (a) COX-2-dependent
eicosanoid(s), which inhibit(s) UV-induced apoptosis of SPIβ cells via
activation of a G protein-coupled receptor (GPCR). Here we show that
in line with SPIα cells expressing 2–3 fold higher levels of PI-TPα
compared with wtNIH3T3 cells, CM from SPIα cells displays a more
pronounced effect on the survival of SPIβ cells than CM fromwtNIH3T3
cells (Fig. 1). The observation that an increase in the concentration of
CM from wtNIH3T3 cells did not result in an anti-apoptotic effect
comparable to CM from SPIα cells suggests that CM from SPIα cells
contains additional anti-apoptotic factors which may be absent from
CM fromwtNIH3T3 cells [unpublished data] [52]. This is conﬁrmed by
TLC analysis of neutral lipid extracts of CM from wtNIH3T3 and SPIα
cells [1]. As a control, the level of PI-TPαwas reduced inwtNIH3T3 cells
by RNAi (data not shown). Unfortunately, the reduced level of PI-TPαsigniﬁcantly diminished the growth rate of thewtNIH3T3 cells and led
to a high level of cell death. Therefore we were unable to evaluate the
anti-apoptotic activity of the medium conditioned by cells with a
reduced level of PI-TPα. On the other hand, these results agreewith the
observation that WRK-1 rat mammary tumour cells, which as a result
of transfection expressed approximately 25% less PI-TPα than control
clones, showed a decreased growth rate [9].
The inhibitory effect of the antagonist SR141716A indicates that the
GPCR activated by the anti-apoptotic factors present in CM from SPIα
cells is the cannabinoid 1 (CB1) or a cannabinoid 1-like receptor [1]. Here
we report that wtNIH3T3 mouse ﬁbroblast cells, SPIα and SPIβ cells
express the CB1 receptor although to different extents. Highest full
length CB1 receptor levels were detected in SPIα cells, intermediate
levels in the wild type cells, whereas SPIβ cells exhibit no full length
CB1 receptor. The immunoreactive banddetectedat ~41 kDa (Fig. 2)may
be due to either alternative splicing of the mouse CB1 receptor gene or
N-terminally truncation of the receptor. Evidence for an alternative
splicingof theCB1 receptor genehas previously been reported in human
cells [53]. On the other hand, several studies report on the amino-
terminal processing of the CB1 receptor [45,54]. Due to the length of the
N-terminal segment, the CB1 receptor cannot be efﬁciently translocated
across the ER membrane. This leads to the degradation of the CB1
receptor by proteasomes and hence, to a low expression level at the
plasmamembrane. In accordance, it was shown in baby hamster kidney
cells that a largenumberof theCB1 receptors areN-terminally truncated
prior to ER translocation [54]. Shorteningof theN-terminal tail, leaving a
~41 kDa CB1 receptor, greatly enhances the stability and cell surface
expression of the receptor without affecting receptor binding to
cannabinoid ligands [45]. In linewith this, the effect of the CB1 receptor
antagonist SR141716A on the protective effect of CM from SPIα cells
indicates that SPIβ cells have a functional CB1 receptor. Since no full
lengthCB1 receptor is detected in SPIβ cells itmaywell be that the cross-
reactive ~41 kDa protein detected in mouse ﬁbroblast cells is a CB1
receptor which is N-terminally truncated. Furthermore, the observed
change in themembrane–lipid composition of SPIβ cells (i.e. a shift from
short chain to long chain ceramide/SM species [55] may hamper
translocation of the N-tail of the CB1 receptor across the ER membrane
resulting in rapid degradation of this full length receptor and a reduced
membrane expression in SPIβ cells. In line with the low level of CB1
receptor in SPIβ cells and its high sensitivity towards UV-induced
apoptosis, several studies report that reduced levels or inhibition of this
receptor enhances apoptosis [52,56,57].
Cannabinoids exert most of their effects by binding the CB1
receptor at the plasmamembrane thereby inhibiting adenylate cyclase
(AC) and N- and P/Q-type voltage-sensitive calcium channels (VSCC),
aswell as activatingmitogen- and stress-activated protein kinase (ERK,
JNK, p38) and Akt/PKB pathways [16–18,28,58,59]. In linewith the fact
that CM fromSPIα cells ismore effective inprotecting SPIβ cells against
apoptosis compared with CM from wtNIH3T3 cells (Fig. 1), Western
blot analysis showed that CM from SPIα cells is muchmore effective in
the activation of the anti-apoptosis p42/p44 MAP kinase and Akt/PKB
pathways. In addition, CM from SPIα cells triggered a faster and more
signiﬁcant activation of the transcription factor NF-κB. The observa-
tion that SR141716A, a speciﬁc CB1 receptor antagonist, shows an
inhibitory effect on the activation of these pathways by CM from
SPIα cells implies that the effect is mediated by the CB1 receptor (Fig.
6). The activation of NF-κB is in agreement with the up regulation of
cyclooxygenase-2 in SPIα cells [1] as the expression of this protein is
controlled by NF-κB [60]. The activation appeared to be rather speciﬁc
as phosphorylation of p38 MAP kinase was not observed (data not
shown). NF-κB activation up regulates the transcription of pro-survival
genes encoding c-IAP1, c-IAP2, and IXAP, the TNF receptor-associated
factors (TRAF1 and TRAF2) and members of the Bcl-2 family, in addi-
tion to up regulating a gene promoting cell proliferation, cyclin D1 a
positive regulator of G1-to-S-phase progression [61–63]. In line with
this, the anti-apoptotic activity present in CM from SPIα cells is likely
Fig. 8. The regulatory role of phosphatidylinositol transfer protein (PI-TPα) in the production of a bioactive eicosanoid. In the model presented, PI-TPα activates a PI-speciﬁc
phospholipase A (PLA) leading to an increased release of arachidonic acid, which is subsequently converted into eicosanoids by COX-2 [1]. A part of these eicosanoids constitute the
survival factor(s), which has anti-apoptotic activity by acting through the activation of a G protein-coupled receptor, possibly a CB1-like receptor. Upon receptor activation, the p42/
p44 MAP kinase and Akt/PKB pathway are activated. On the other hand, the P38 MAP kinase and PLC pathways are not activated.
1705M. Schenning et al. / Biochimica et Biophysica Acta 1783 (2008) 1700–1706to exert its protective effect by the expression of all these proteins.
Since the activation of the Akt/PKB pathwayalso affects transcriptional
factors like CREB, YAK and Forkhead, the activation or inhibition of
other pathways affecting cells survival and cell proliferation is likely.
Several studies show a relationship between PI-TPα and the G
protein-couple receptor-mediated activation of phospholipase C (PLC)
upon addition of PI-TPα to cytosol depleted cells [11,64]. By using SPIβ
cells transfected with the plasmid containing cDNA encoding YFP-
tagged C2 domain from PKC, we demonstrated that addition of CM
from SPIα cells had no effect on the translocation of the ﬂuorescent
probe. Since the positive regulator of PLC (UTP) did result in
translocation (Fig. 7), it appears that the cellular effect of the anti-
apoptotic factor is independent of PLC activation. This is in line with
the fact that CB1 receptor signalling leads to the activation of the G
protein Giα which does not activate PLCβ [65–68]. This observation
does not necessarily contradict the studies by Cockcroft et al. that PI-
TPα acts directly in the cell through activation of PLC [69]. In the latter
case, it is proposed that PI-TPα is essential for enhanced formation of
PI(4)P and PI(4,5)P2 as substrates of PLC. The datawe presented here is
summarized in a model representing a possible mechanism by which
cell survival depends on PI-TPα (Fig. 8). In the model presented, PI-
TPα activates a PI-speciﬁc phospholipase A (PLA) [10]. This implies
that, in addition to lysoPI and glyceroPI, a signiﬁcant amount of
arachidonic acid is produced because PI is highly enriched in this fatty
acid [70]. Arachidonic acid is the main precursor for the synthesis of
eicosanoids and is subsequently converted by COX-2 [1]. A part of
these eicosanoids constitute the survival factor(s), which has/have
anti-apoptotic activity by acting through the activation of a G protein-
coupled receptor, most likely the CB1 or a CB1-like receptor. Upon
receptor activation, the anti-apoptotic p42/p44 MAP kinase and Akt/
PKB pathways are activated, whereas the PLC/DAG and p38 MAP
kinase pathways remain unchanged. The subsequent activation of the
transcription factor NF-κB, a positive regulator of COX-2, is in line with
the increased levels of this enzyme observed in SPIα cells [1].Acknowledgements
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